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Abstract
Background: Alpha-melanocyte-stimulating-hormone (α-MSH) has marked anti-inflammatory potential. Proinflammatory
cytokines are critical mediators of the disturbed cartilage homeostasis in osteoarthritis, inhibiting anabolic activities and
increasing catabolic activities in chondrocytes. Since human chondrocytes express α-MSH receptors, we evaluated the
role of the peptide in modulating chondrocyte production of pro-inflammatory cytokines, matrix metalloproteinases
(MMPs), tissue inhibitors of MMPs (TIMPs), inducible nitric oxide synthase (iNOS) and nitric oxide (NO) in response to
interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α).
Methods: Human articular chondrocytes were obtained from osteoarthritic joint cartilage from subjects undergoing hip
routine arthroplasty procedures. The cells were cultured with or without α-MSH in the presence of IL-1β or TNF-α.
Cell-free supernatants were collected and cells immediately lysed for RNA purification. Expression of cytokines, MMPs,
TIMPs, iNOS was determined by Reverse Transcription Real-time Polymerase Chain Reaction and enzyme-linked
immunosorbent assay. Griess reaction was used for NO quantification.
Results: Gene expression and secretion of IL-6, IL-8, MMP-3, MMP-13 were significantly increased in IL-1β or
TNF-α-stimulated chondrocytes; α-MSH did not modify the release of IL-6 or IL-8 while the peptide significantly reduced
their gene expression on TNF-α-stimulated cells. A significant inhibition of MMP3 gene expression and secretion from
IL-1β or TNFα-stimulated chondrocytes was induced by α-MSH. On the other hand, α-MSH did not modify the release
of MMP-13 by cytokine-stimulated chondrocyte but significantly decreased gene expression of the molecule on
TNF-α-stimulated cells. Detectable amount of TIMP-3 and TIMP-4 were present in the supernatants of resting
chondrocytes and a significant increase of TIMP-3 gene expression and release was induced by α-MSH on unstimulated
cells. TIMP-3 secretion and gene expression were significantly increased in IL-1β-stimulated chondrocytes and α-MSH
down-regulated gene expression but not secretion of the molecule. TIMP-4 gene expression (but not secretion) was
moderately induced in IL-1β-stimulated chondrocytes with a down-regulation exerted by α-MSH. IL-1β and TNF-α were
potent stimuli for NO production and iNOS gene expression by chondrocytes; no inhibition was induced by α-MSH on
cytokine-stimulated NO production, while the peptide significantly reduced gene expression of iNOS.
Conclusions: Our results underscore a potential anti-inflammatory and chondroprotective activity exerted by α-MSH,
increasing TIMP-3 gene expression and release on resting cells and down- modulating TNF-α-induced activation
of human chondrocytes. However, the discrepancy between the influences exerted by α-MSH on gene expression
and protein release as well as the difference in the inhibitory pattern exerted by α-MSH in TNF-α- or IL-1β-stimulated
cells leave some uncertainty on the role of the peptide on chondrocyte modulation.
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Background
Osteoarthirits (OA) is a chronic rheumatic disease charac-
terized by cartilage degradation and loss, subchondral
bone remodelling, and possible synovial inflammation.
The precise cause of OA is unknown. A failure of chon-
drocytes to maintain the balance between synthesis and
degradation of the cartilage extracellular matrix is consid-
ered a significant factor in the loss of cartilage [1].
The assumed mechanisms involved in chondrocyte
dysregulation and/or apoptosis include mechanical stress,
age-related functional changes and altered production of
pro-inflammatory cytokines, predominantly interleukin-1β
(IL-1β) and tumor necrosis factor-α (TNF-α), that induce
production of oxygen radicals and proteinases such as
matrix metalloproteinases (MMPs) and aggrecanases [2].
These observations suggested that anti-cytokine and
anti-oxydant compounds could have chondroprotective
effects providing novel therapeutic opportunities for
OA treatment [3, 4].
α-Melanocyte-stimulating hormone (α-MSH) is an
endogenous tridecapeptide that exerts multiple effects
on host cells [5]. The natural peptide and its synthetic
analogs inhibit inflammatory response in experimental
models of acute and chronic disorders, including inflam-
matory bowel diseases, allergy, adjuvant arthritis, and
sepsis [6–9]. α-MSH interacts with host cells through
activation of four of the five recognized melanocortin
receptors (MCR), specifically MCR 1, 3, 4 and 5 [9]. The
anti-inflammatory action of the peptide depends primar-
ily on inhibition of cytokine production by target cells,
although other leukocyte functions, including reactive
oxygen intermediate (ROI) production, nitric oxide
(NO) generation and release of proteolytic enzymes, are
likewise influenced [7–9].
In spite of substantial evidence suggesting a beneficial
effect of melanocortin peptides in control of numerous
inflammatory disorders and the observation that hu-
man chondrocytes express MCR [10], only recently the
therapeutic potential of melanocortins in OA has been
explored. Yoon et al. [11], using a human chondrosar-
coma cell line (HTB-94) showed that α-MSH inhibited
TNF-α-induced expression of MMP-13, through a de-
crease in mitogen-activated protein kinase (MAPK) p38
phosphorylation and subsequent activation of nuclear
factor-κB (NF-κB). In human articular chondrocytes,
α-MSH decreased IL-1β and TNF-α mRNA but in-
creased the secretion of TNF-α, IL-6 and Transforming
Growth Factor-β1 (TGF-β1) [10]. In addition, in rodent
chondrocytes, adrenocorticotropin (ACTH) treatment
promoted development of the chondrocyte phenotype
through activation of the MCR 3 [12]. Recently Kaneva
et al. [13], using a human chondrocyte cell line (C-20/
A4) demonstrated that melanocortin peptides strongly
modulated chondrocyte function: the molecules inhibited
TNF-α-induced production of pro-inflammatory cytokines
whilst increasing production of the anti-inflammatory and
chondroprotective cytokine interleukin-10 (IL-10); de-
creased gene expression of MMPs; prevented chondrocyte
apoptosis by inhibiting TNF-α induced caspase-3 and -7
activation.
The main obstacle in studies on human chondrocyte
biology depends on the difficulty to obtain primary articu-
lar chondrocytes as these cells lose chondrocytic pheno-
type when expanded and cultured in monolayer. In the
present study we evaluated the capacity of primary articu-
lar human chondrocytes to produce pro-inflammatory
cytokines, MMPs, tissue inhibitors of MMPs (TIMPs) and
NO in response to pro-inflammatory cytokines (IL-1ß and
TNF-α). In parallel experiments the effects of α-MSH in
modulation of mediator production were investigated.
Methods
Chondrocyte isolation and culture
Samples of adult human articular cartilage were harvested
from subjects undergoing hip routine arthroplasty proce-
dures at the Istituto Ortopedico Galeazzi IRCCS, Milan.
This study did not undergo ethical approval since the
cartilage was collected as waste material after receiving
patients signed informed consent and the approval of the
Institutional Review Board (IRCCS Istituto Ortopedico
Galeazzi).
Minced cartilage fragments (2-3 mm2) were submitted
to enzymatic digestion with 0.15 % collagenase type II
(Worthington Biochemical Corporation, Lakewood, NJ,
USA) overnight at 37 °C., as previously described [14].
Freshly isolated chondrocytes were plated for expansion
at a density of 1x104 cells/cm2 and cultured with
complete medium (CM) containing Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 10 % fetal
bovine serum (FBS, Lonza Group Ltd, Basel, CH), 1 mM
sodium pyruvate, 100 mM HEPES buffer, 100 U/mL
penicillin, 100 μg/mL streptomycin, 0.29 mg/mL L-glu-
tamine [15]. When the cells reached 80–90 % of conflu-
ence, they were detached with trypsin/EDTA (0.5 %
trypsin/0.2 % EDTA and washed before performing the
assays. Human chondrocytes were placed in 15 ml tissue
culture tubes for 4 h with either phosphate buffered
solution (PBS) (control) or α-MSH 10−6M. The tests
employed the analogue Nle4,DPhe7-α-MSH (NDP-MSH),
a non specific MC agonist that exerts similar effects rela-
tive to the natural α-MSH and is generally preferred for its
greater chemical stability [16]. The cells were then
cultured for 40 h in the presence or absence of 10 ng/mL
human recombinant IL-1β or 10 ng/mL human recombin-
ant TNF-α [17]. In our preliminary experiments, these
culture conditions had been found to be optimal to acti-
vate human chondrocytes. Where not otherwise specified,
Sigma-Aldrich (Poole, Dorset, UK) products were used.
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Cell-free supernatants were collected and stored at -20 °C
and cells immediately lysed for RNA purification.
Cytokine quantification by ELISA
A qualitative commercial enzyme-linked immunosorbent
assay test (Multi-analyte ELISArray kit (SABiosciences -
QIAGEN, Maryland, USA) has been used to simultan-
eously profile the level of multiple cytokines (IL-1α, IL-1ß,
IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17A, IFNγ, TNF-α,
GM-CSF) in cell culture supernatants.
A cutoff of twice the absorbance value (read at 450 nm)
of the negative control for every cytokine (A450) was used
and the results were reported as positive (A450 ≥ specific
cutoff) or negative (A450 < specific cutoff).
Protein concentration of detectable cytokines IL-6,
IL-8, MMP-3, MMP-13 (Boster Biological Technology,
Fremont, CA, USA), TIMP-3 and TIMP-4 (R&D Sys-
tems, Minneapolis, MN, USA) was then determined in
cell-free supernatants using quantitative commercially
available ELISA kits.
Quantification of nitrites
The total NO production was measured using a commer-
cial kit that involves the enzimatic conversion of nitrate to
nitrite by the enzyme Nitrate Reductase (Enzo Life Sci-
ences - Farmingdale, NY, USA). Briefly, 50 μl of the cul-
ture supernatant and 50 μl of Nitrate Reductase were
mixed and incubated for 30 min at 37 °C in 96-well plates.
One hundred microliters of the Griess reagent were added
to the wells and incubated for further 10 min before read-
ing the optical density at 540–570 nm. The nitrite concen-
tration was calculated from a standard curve of sodium
nitrate and expressed as μmole/l.
RNA purification
Total RNA was isolated from chondrocyte lysates by
anion exchange chromatography using RNeasy MinE-
lute columns (RNeasy Mini Kit, Qiagen Inc., Hilden,
Germany). Briefly, cell lysates were added (v/v) to 70 %
ethanol and immediately transferred to an RNeasy col-
umn. DNase I treatment (Qiagen) was performed to re-
move genomic DNA contamination. After two washes
in ethanol-based buffer (Buffer RPE, Qiagen), RNA
were eluted in RNase-free water and then quantified by
optical density measurement using Nanodrop ND-100
spectrophotometer (Nanodrop Technologies, Wilmington,
DE). Each sample showed a 260/280 ratio between 1.8 and
2. RNA integrity was assessed by electrophoresis on
denaturing agarose–formaldehyde gels.
Table 1 Gene Symbols and Assay ID of the genes evaluated
using Real-time RT-PCR
Gene
name
Gene symbol Assay ID
IL6 interleukin 6 Hs00174131_m1
IL8 interleukin 8 Hs00174103_m1
MMP3 matrix metalloproteinase 3 Hs00968305_m1
MMP13 matrix metalloproteinase 13 Hs00233992_m1
TIMP1 TIMP metallopeptidase inhibitor 1 Hs00171558_m1
TIMP3 TIMP metallopeptidase inhibitor 3 Hs00165949_m1
TIMP4 TIMP metallopeptidase inhibitor 4 Hs00162784_m1
ACTB actin, beta Hs99999903_m1
GAPDH glyceraldehyde-3-phosphate
dehydrogenase
Hs99999905_m1
RPLP0 ribosomal protein, large, P0 Hs99999902_m1
HPRT1 hypoxanthine phosphoribosyltransferase 1 Hs99999909_m1
Table 2 Effect of IL-1β and TNF-α on secretion of different
molecules by human chondrocytes
Stimulus
Molecules in the
Supernatants (ng/mL)
Medium IL-1β TNF-α
IL-6 3.0 ± 0.2 367 ± 4.9* 70 ± 3.7*
IL-8 0.0 781 ± 32* 120 ± 5.6*
MMP-3 2.0 ± 0.00 14500 ± 400* 8100 ± 50*
MMP-13 8.1 ± 0.5 71.0 ± 8.0* 35.3 ± 2.7*
TIMP-3 1.63 ± 0.12 2.71 ± 0.05° 1.23 ± 0.01 ns
TIMP-4 0.11 ± 0.01 0.12 ± 0.01 ns 0.12 ± 0.01 ns
NO (μM) 19.5 ± 3.5 102.8 ± 32.6* 95.8 ± 36.9*
Primary human chondrocytes were cultured for 40 h in medium or in the
presence of 10 ng/mL IL-1ß or TNF-α. The cell-free supernatants were collected
and the concentration of interleukins, MMPs, TIMPs and NO were measured.
Data from 4 separate experiments (± S.E.M.) are shown
* p < 0.0001; °p < 0.002; ns: not significant vs medium
Table 3 Effect of IL-1ß and TNF-α on gene expression of different
molecules in human chondrocytes
Stimulus
Relative gene expression for IL-1β TNF-α
IL-6 2767 ± 176* 680 ± 49*
IL-8 5090 ± 271* 1088 ± 78*
MMP-3 112 ± 10.0* 71 ± 6.5*
MMP-13 7.5 ± 2.0* 6.5 ± 0.5*
TIMP-3 3.4 ± 0.7° 1.0 ± 0.1 ns
TIMP-4 1.9 ± 0.2° 1.0 ± 0.05 ns
iNOS 1656 ± 100* 1663 ± 110*
Primary human chondrocytes were cultured for 40 h in medium or in the
presence of 10 ng/mL IL-1ß or TNF-α. RNA was purifiedd and analyzed by
Real-time RT-PCR. Gene expression data were calculated with the ΔCT method
and using HPRT1 and GAPDH as reference genes. Relative expression was obtained
comparing samples to untreated control whose gene expression was considered
as baseline. Data from 4 separate experiments (± S.E.M.) are shown
* p < 0.0001; °p < 0.02; ns: not significant vs untreated controls
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Reverse Transcription Real-time Polymerase Chain Reaction
(Real-time RT-PCR) analysis
Gene expression was evaluated by Real-Time Reverse
Transcription-Polymerase Chain Reaction (RT-PCR) ana-
lysis. Two micrograms of total RNA were reverse tran-
scribed to single stranded cDNA using SuperScript VILO
cDNA Synthesis Kit (Life Technologies, Foster City, CA)
according to the manufacturer's instructions. Real-time
PCR based on TaqMan chemistry was performed with
20 ng of retrotranscribed RNA, 1X FastStart Universal
Probe Master (Roche Diagnostics GmbH, Mannheim,
Germany), and predesigned 900 nM primers and 250 nM
probe mix (Taqman Gene Expression Assays, Life Tech-
nologies, (assay IDs are listed in Table 1) in a final volume
of 10 μl. Amplification reactions were carried out on an
ABI PRISM 7900HT sequence detection system (Applied
Biosystems, Life Technologies) with the following thermal
profile settings: an initial step of 10 min at 95°c to activate
the FastStart Taq DNA polymerase, then 50 cycles of 95 °
C for 10 s and 60 °C for 30 s. Three independent PCR
amplification experiments were performed for each tran-
script. Fluorescence intensities were converted in thresh-
old cycles (Ct) using ABI Prism SDS 2.3 software (Life
Technologies); baseline and threshold were set by auto-
matic analysis. Relative quantification of target gene
expression was calculated with the ΔCt method, using the
average Ct across basal samples as calibrator for each
gene. Analysis of reference genes stability, performed with
the geNorm software, indicated HPRT1 and GAPDH as
the most stable [18].
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Fig. 1 Effect of α-MSH on IL-6 and IL-8 secretion (a) and gene expression (b) in IL-1β-stimulated chondrocytes. Human primary chondrocytes
were incubated for 4 h at 37 °C with 10−6M α-MSH and further cultured for 40 h in the presence or absence of 10 ng/mL IL-1β. IL-6 and IL-8
concentration in the supernatans (a) and gene expression (b) were then measured. Data from 4 separate experiments (± S.E.M.) are shown.
*p < 0.0001 vs Medium
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Statistical analysis
The data are expressed as the mean ± standard error of
the mean (S.E.M.) from 4 determinations as indicated.
Statistical analysis was done using Student’s t test for
unpaired data, as appropriate. Differences were consid-
ered to be statistically significant at P < 0.05.
Results
Effect of pro-inflammatory cytokines on human
chondrocytes
Of the twelve cytokines evaluated in the supernatants of
IL-1β or TNF-α-stimulated chondrocytes with a qualita-
tive ELISA test (IL-1α, IL-1ß IL-2, IL-4, IL-6, IL-8, IL-
10, IL-12, IL-17α, IFNγ, TNF-α, GM-CSF), significant
levels were observed only for IL-6 and IL-8 (not
shown). The protein concentration of these two cyto-
kines is shown in Table 2. Gene expression of IL-6 and
IL-8 was also significantly increased in IL-1β or TNF-
α-stimulated chondrocytes (Table 3). Increased levels of
MMP-3 and MMP-13 in the supernatants (Table 2) as
well as enhanced gene expression (Table 3) were ob-
served in cytokine-stimulated chondrocytes, with IL-1β
being the most potent stimulus.
Low but detectable amounts of TIMP-4 (Table 2)
were present in the supernatants of non-stimulated
chondrocytes with no increased secretion after stimula-
tion by IL-1β or TNF-α. TIMP-4 gene expression was
moderately induced by IL-1β while there were no
changes when the stimulus was TNF-α (Τable 3).
TIMP-3 was also present in the supernatants of resting
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Fig. 2 Effect of α-MSH on IL-6 and IL-8 secretion (a) and gene expression (b) in TNF-α-stimulated chondrocytes. Human primary chondrocytes were
incubated for 4 h at 37 °C with 10−6M α-MSH and further cultured for 40 h in the presence or absence of 10 ng/mL TNF-α. IL-6 and IL-8 concentration in the
supernatans (a) and gene expression (b) were then measured. Data from 4 separate experiments (± S.E.M.) are shown. *p<0.0001 vs Medium; °p<0.05 vs TNF-α
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chondrocytes and its secretion (Table 2) as well as gene
expression (Table 3) were significantly increased by IL-
1β but not by TNF-α stimulation. Both IL-1β and TNF-
α were potent stimuli for NO production (Table 2) and
iNOS gene expression (Table 3).
Effect of α-MSH on human chondrocytes
Pre-treatment of chondrocytes with 10−6M α-MSH did
not modify the release of IL-6 or IL-8 by IL-1ß (Fig. 1) or
TNF-α (Fig. 2) stimulated chondrocytes. On the other
hand, while only slightly decreased gene expression of IL-
6 and IL-8 was observed when the cells were stimulated
with IL-1ß (Fig. 1), the reduction became significant when
the stimulus was TNF-α (Fig. 2)
A significant inhibition of MMP-3 gene expression
and secretion from IL-1β- or TNF-α-stimulated chon-
drocytes was induced by α-MSH (Fig. 3). On the other
hand, α-MSH did not modify the release of MMP-13 by
cytokine-stimulated chondrocyte but the peptide caused
a decreased gene expression of the molecule that was
significant for TNF-α-stimulated cells (Fig. 4)
α-MSH did not modify TIMPs secretion by cytokine-
stimulated chondrocyte (Figs. 5 and 6) but the peptide
down-regulated the IL-1β-induced gene expression of
TIMP-3 (Fig. 5) and TIMP-4 (Fig. 6). Of interest, a
significant increase of TIMP-3 gene expression and re-
lease was induced by α-MSH (three fold increase) on
unstimulated cells (Fig. 5).
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Fig. 3 Effect of α-MSH on MMP-3 secretion (a) and gene expression (b) in IL-1β or TNF-α-stimulated chondrocytes. Human primary chondrocytes
were incubated for 4 h at 37 °C with 10−6M α-MSH and further cultured for 40 h in the presence or absence of 10 ng/mL IL-1β or TNF-α. MMP-3
concentration in the supernatans (a) and gene expression (b) were then measured. Data from 4 separate experiments (± S.E.M.) are shown. *p < 0.0001
vs Medium; §p < 0.001 vs IL-1β; °p < 0.01 vs TNF-α; °°p < 0.001 vs TNF-α
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No inhibition was induced by α-MSH on cytokine-
stimulated NO production but the peptide was able to
reduce gene expression of iNOS2, the enzyme involved
in inducible syntesis of nitric oxide (Fig. 7).
Discussion
The data show that stimulation of human primary chon-
drocytes with IL-1β or TNF-α induces an inflammatory
phenotype. Both cytokines induced gene expression and
secretion of IL-6, IL-8, MMP-3 and MMP-13 associated
with a significant production of NO. These results con-
firm a significant chondrocyte responsiveness to ex-
ogenous pro-inflammatory stimuli with amplification of
the inflammatory response and possible local cartilage
degradation. Under our experimental conditions the
anti-inflammatory peptide α-MSH did not modify re-
lease or gene expression of IL- 6, IL-8, MMP-13,
MMP-3 in resting chondrocytes. These results are not
consistent with previous observations by Grässel et al.
[10] who, using different chondrocyte culture condi-
tions (micromass pellets) reported an α-MSH-induced
down-regulation of IL-1β and TNF-α gene expression
and an increased secretion of IL-6 and TNF-α in
human chondrocytes. Of interest, we observed that α-
MSH was able to induce gene expression and secretion
of TIMP-3 in resting cells. These results suggest a
ng
/m
L
0
20
40
60
80
100
STIMULI
re
la
tiv
e 
ex
pr
es
si
on
0
2
4
6
8
MMP13
aMSH IL-1 IL1+
aMSH
TNF TNF+
aMSH
*A
B
*
*
*
Medium
o
Fig. 4 Effect of α-MSH on MMP-13 secretion (a) and gene expression (b) in IL-1β or TNF-α-stimulated chondrocytes. Human primary chondrocytes
were incubated for 4 h at 37 °C with 10−6M α-MSH and further cultured for 40 h in the presence or absence of 10 ng/mL IL-1β or TNF-α. MMP-13
concentration in the supernatans (a) and gene expression (b) were then measured. Data from 4 separate experiments (± S.E.M.) are shown. *p < 0.0001
vs Medium; °p < 0.05 vs TNF-α
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potential role for α-MSH in the maintenance of cartilage
homeostasis. Indeed the anticatabolic influence of TIMP-3
as an inhibitor of molecules implicated in cartilage deg-
radation, including MMP and aggrecanase-2, is well
recognized [19].
When the capacity of α-MSH to modulate IL-1β or
TNF-α-induced chondrocyte activation was evaluated,
we observed that the peptide did not exert anti-oxidative
activity on human chondrocytes as it did not modify
cytokine-induced NO production. On the other hand,
α-MSH significantly inhibited MMP-3 gene expression
and secretion induced by both cytokines further suggest-
ing an anticatabolic role of the peptide. In TNF-α-
stimulated chondrocytes the peptide significantly reduced
gene expression of IL-6, IL-8, and MMP-13. Conversely,
there was no substantial effect in IL-1β-activated cells.
These results are consistent with those of Yoon et al. [11]
who showed that α-MSH inhibited TNF-α-induced
MMP-13 gene expression in a human chondrosarcoma
cell line.
The present data are partly consistent with those of
Kaneva et al. [13] who reported an inhibitory effect of α-
MSH on pro-inflammatory cytokine release (IL-1, IL-6,
IL-8) and on MMP-1, MMP-3, MMP-13 gene expression
in a TNF-α-stimulated human chondrocyte cell line.
Collectively, these results underscore a potential anti-
inflammatory and chondroprotective activity exerted by
α-MSH in TNF-α-stimulated human chondrocytes.
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Fig. 5 Effect of α-MSH on TIMP-3 secretion (a) and gene expression (b) in IL-1β or TNF-α-stimulated chondrocytes. Human primary chondrocytes
were incubated for 4 h at 37 °C with 10−6M α-MSH and further cultured for 40 h in the presence or absence of 10 ng/mL IL-1β or TNF-α.
TIMP-3 concentration in the supernatans (a) and gene expression (b) were then measured. Data from 4 separate experiments (± S.E.M.) are
shown. *P < 0.002 vs Medium; **p < 0.001 vs Medium; °p < 0.02 vs Medium; °°p < 0.002 vs Medium; §p < 0.05 vs IL-1β
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In our experimental conditions, the α-MSH-induced
inhibition of cytokine-stimulated gene expression of IL-
6, IL-8 and MMP-13, and the down-regulation of IL-
1β-induced increase in TIMP-3 and TIMP-4 gene
expression were not accompanied by a parallel reduc-
tion in protein release. A similar discordance between
gene expression and protein secretion was previously
reported by Grässel et al. [10] using α-MSH-treated
micromass pellet cultures.
Although the discrepancy between influences on gene
expression and protein release does not have a definite
explanation, it may be secondary to an incomplete or
late inhibition of gene expression by α −MSH compared
to the activation induced by pro-inflammatory cytokines
in vitro.
The biological significance of the difference in the in-
hibitory pattern exerted by α-MSH in TNF-α-stimulated
chondrocytes (inhibition of IL-6, IL-8 and MMPs gene
expression) relative to IL-1β-stimulated cells (inhibition
of TIMP-3 and TIMP-4 gene expression) is likewise
unclear. Both IL-1β and TNF-α exert their biological
responses mainly through the activation of nuclear factor-
κB (NF-κB) signalling pathway and NF-kB suppression is
considered the key molecular mechanism of the anti-
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Fig. 6 Effect of α-MSH on TIMP-4 secretion (a) and gene expression (b) in IL-1β or TNF-α-stimulated chondrocytes. Human primary chondrocytes
were incubated for 4 h at 37 °C with 10−6M α-MSH and further cultured for 40 h in the presence or absence of 10 ng/mL IL-1β or TNF-α. TIMP-4
concentration in the supernatans (a) and gene expression (b) were then measured. Data from 4 separate experiments (± S.E.M.) are shown. *p < 0.02 vs
Medium; °P < 0.05 vs IL-1β
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inflammatory effect of α-MSH [9]. It is possible that differ-
ent concentrations of the peptide are required to inhibit
the activation induced by different cytokines in vitro. An
interference exerted by α-MSH on membrane cytokine re-
ceptors could be also considered but, while it has been
demonstrated that α-MSH potently and selectively reduce
membrane binding of IL-1β to T-cell clones, we have no
knowledge of similar data for TNF-α.
Conclusions
The present results indicate that α-MSH exerts chondro-
protective activity suggesting a potential role of α-MSH in
the maintenance of cartilage homeostasis although the
role of the peptide in the control of chondrocyte activation
remains to be defined.
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